Lv1
20 积分 2026-09-24 加入
HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers
13小时前
求助中
Treatment advances in small cell lung cancer (SCLC)
1天前
已完结
The changing therapeutic landscape of small-cell lung cancer
3天前
已完结
Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
7天前
已完结
DLL3 expression in neuroendocrine carcinomas: a comparative analysis across tumor origins
8天前
已完结
Delta-Like Ligand 3 Expression by Immunohistochemistry in Rare Neuroendocrine Neoplasms and Associated Response to Off-Label Tarlatamab Treatment
8天前
已关闭
Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors
8天前
已完结
皖公网安备34019202002308
